From the Department of Paediatrics & Child Health, SA-MRC Unit on Child Adolescent Health, University of Cape Town, Cape Town, South Africa.
FAMCRU, Department of Paediatrics & Child Health, Stellenbosch University, Cape Town, South Africa.
Pediatr Infect Dis J. 2020 Nov;39(11):1035-1039. doi: 10.1097/INF.0000000000002826.
Little is known about hospitalization in African adolescents with perinatally acquired HIV (PHIV+ adolescents). We described the incidence and causes of hospitalization in participants enrolled in the Cape Town Adolescent Antiretroviral Cohort in South Africa.
Data collected from July 2013 to October 2018 from PHIV+ and HIV- adolescents were analyzed. Participants were assessed every 6 months and data on intercurrent hospitalization were abstracted. Causes of hospitalizations were classified according to ICD-10 codes. Descriptive statistics, time-to-event analysis and Poisson regression were used to describe causes and incidence and to determine incidence rate ratios for factors associated with hospitalization.
Five hundred fifteen PHIV+ and 109 HIV- participants had a median follow-up of 4.1 years [interquartile range (IQR): 3.7-4.6]. At enrollment HIV+ participants had a median duration of ART of 7.6 years (IQR: 4.6-9.2), median CD4 count of 713 cells/mm (IQR: 561.0-957.5) and 387 (75%) had a viral load <50 copies/mL. There were 149 hospital admissions over 64 months. Crude incidence rates for hospitalization were 6.6 [95% confidence interval (CI): 5.7-7.8] and 2.2 (95% CI: 1.2-4.3) per 100-person-years (P = <0.01) in HIV + and HIV-, respectively. Ninety of 149 (60%) admissions in HIV+ participants were classified as non-infectious, 36/149 (24%) were infectious and 23/149 (16%) were "other HIV-related" or "unknown." Older age (15-19 years) and maintaining a CD4 >500 cells/cm were associated with decreased risk of hospitalization: adjusted incidence rate ratios of 0.61 (CI: 0.44-0.86, P = <0.01) and 0.68 (CI: 0.49-0.94, P = 0.02), respectively.
PHIV+ adolescents had a high incidence of hospitalization despite ART. Strategies addressing infectious and non-infectious morbidity must be strengthened.
关于在非洲青少年中获得围产期艾滋病毒(PHIV + 青少年)的住院情况,我们知之甚少。我们描述了在南非开普敦青少年抗逆转录病毒队列中招募的参与者的住院发生率和原因。
从 2013 年 7 月至 2018 年 10 月,对 PHIV + 和 HIV-青少年收集的数据进行了分析。每 6 个月评估一次参与者,并提取与住院有关的资料。根据 ICD-10 代码对住院原因进行分类。使用描述性统计、时间事件分析和泊松回归来描述原因和发生率,并确定与住院相关的因素的发生率比。
515 名 PHIV + 和 109 名 HIV-参与者的中位随访时间为 4.1 年[四分位距(IQR):3.7-4.6]。在入组时,HIV+参与者的 ART 中位持续时间为 7.6 年(IQR:4.6-9.2),中位 CD4 计数为 713 个细胞/mm(IQR:561.0-957.5),387 个(75%)病毒载量<50 拷贝/ml。64 个月内有 149 次住院。HIV + 和 HIV-参与者的住院粗发生率分别为 6.6 [95%置信区间(CI):5.7-7.8]和 2.2(95% CI:1.2-4.3)/100 人年(P <0.01)。在 HIV + 参与者中,90/149(60%)的入院被归类为非传染性,36/149(24%)为传染性,23/149(16%)为“其他 HIV 相关”或“未知”。年龄较大(15-19 岁)和保持 CD4 >500 个细胞/cm 与住院风险降低相关:调整后的发病率比分别为 0.61(CI:0.44-0.86,P <0.01)和 0.68(CI:0.49-0.94,P = 0.02)。
尽管进行了抗逆转录病毒治疗,PHIV + 青少年的住院率仍很高。必须加强针对传染性和非传染性发病率的策略。